Key result
TRPV3 receptor antagonists modulate evoked signals peripherally and dampen both evoked and nonevoked pain through supraspinal descending modulation in rats.
Central TRPV3 blockade may be required for full analgesia; leaves open optimal antagonist design and clinical translation.
Recent studies have linked TRPV3 to pain modulation, and much of this work has focused on its role in the skin-primary afferent interface. In this electrophysiological study, we demonstrate that receptor antagonists modulate evoked signals through peripheral mechanisms but blockade of supraspinal TRPV3 receptors contributes to dampening both evoked and nonevoked "pain" through descending modulation. Thus, the full therapeutic potential of TRPV3 antagonists may only be realized with the ability to access receptors in the brain.
No takes yet. Share an insight, caveat, or question.
McGaraughty et al. (2017) studied Pain. TRPV3 receptor antagonists was evaluated on Evoked and nonevoked pain signals. TRPV3 receptor antagonists modulate evoked signals peripherally and dampen both evoked and nonevoked pain through supraspinal descending modulation in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: